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compared to the planning CT: the CTV70 shrinkage (in cc) and 
the PG dose difference (p<0.01 and R²=0.71). 
 
 
Conclusions: Monitoring the PG volumes and the head and 
neck thickness during the course of treatment allows to 
identify PG overdose at the fraction. The first weekly CT can 
be used to predict PG overdose and therefore to target the 
patients for a dose-guided ART strategy. Other series of 
patients are needed to confirm our nomograms.  
   
PO-0643   
Volumetric versus anatomical outlining: target delineation 
conformity in a multi-centre head and neck trial 
H. Yang1, H. Baines2, J. Conibear3, M. Evans4, A. Hartley5, J. 
Henderson2, C. Nutting6, T. Roques7, H. Mehanna8 
1Mount Vernon Cancer Centre, Radiotherapy Trials Quality 
Assurance, London, United Kingdom  
2Royal Marsden NHS Foundation Trust, Radiotherapy Trials 
Quality Assurance, London, United Kingdom  
3Barts Health NHS Trust, Department of Radiotherapy, 
London, United Kingdom  
4Velindre Cancer Centre, Department of Clinical Oncology, 
Cardiff, United Kingdom  
5University Hospitals Birmingham NHS Foundation Trust, 
Cancer Centre, Birmingham, United Kingdom  
6Royal Marsden NHS Foundation Trust, Head and Neck Unit, 
London, United Kingdom  
7Norfolk and Norwich University Hospital NHS Foundation 
Trust, Department of Oncology, Norwich, United Kingdom  
8Institute of Head and Neck Studies and Education, School of 
Cancer Studies, Birmingham, United Kingdom  
 
Purpose/Objective: Accurate target volume delineation is 
essential in the treatment of head and neck cancers using 
intensity-modulated radiotherapy (IMRT). To adapt to the 
increasing use of a volumetric outlining approach in this 
setting, contouring using a volumetric expansion method was 
incorporated with anatomical delineation into the protocols 
for De-ESCALaTE HPV, a multi-centre phase III trial for 
patients with oropharyngeal squamous cell carcinomas. 
As part of radiotherapy trials quality assurance, we evaluate 
the conformity of clinician outlining between these two 
approaches for target volume delineation. 
Materials and Methods: The first submissions of two pre-
accrual outlining benchmark cases (case 1: unilateral neck 
treatment; case 2: bilateral neck treatment) were analysed 
and compared against the trials management group (TMG) 
consensus contours for both delineation methods. The high 
dose clinical target volume (CTV) and prophylactic dose CTV 
were quantitatively assessed using Dice Similarity Coefficient 
(DSC) described by the formula:  
  
where A and B represent regions of interest. 
Results: Anatomical and volumetric outlining was assessed 
for 13 and 11 centres respectively. There was an overlap of 5 
centres which changed to using the volumetric approach 
after the protocol amendment. 
The mean DSC for delineation of high dose CTV was 
systemically greater for volumetric (case 1: 0.82, range 0.69 
– 0.96; case 2: 0.86, range 0.76 – 0.92) than anatomical (case 
1: 0.69, range 0.59 – 0.75; case 2: 0.71, range 0.60 – 0.77) 
outlining for both benchmark cases (case 1: p=0.021; case 2: 
p<0.001). 
There was no statistical difference in the mean DSC for 
prophylactic dose CTV delineation between the 2 outlining 
methods (case 1: p=0.601, case 2: p=0.735). In case 1 the 
mean DSC was 0.59 (range 0.41 – 0.70) and 0.64 (range 0.41 – 
0.82), in case 2 the mean DSC was 0.67 (range 0.61 – 0.75) 
and 0.68 (range 0.49 – 0.81) for volumetric and anatomical 
outlining respectively. 
There was greater concordance in high dose CTV delineation 
compared to prophylactic dose CTV for both benchmark cases 
using either of the two outlining methods. 
Conclusions: The volumetric approach to head and neck 
outlining appears to improve the consistency of high dose 
CTV delineation between centres and the trial consensus 
contours, suggesting that incorporating a geometric margin 
around the GTV, edited for air/bone, is likely to be less open 
to interpretation than anatomical outlining. Both delineation 
methods give rise to similar conformity for prophylactic dose 
CTV outlining, although there is more variation compared to 
high dose CTV. Adaptation of radiotherapy guidelines within 
the course of a trial can improve the concordance of clinician 
target volume definition. In addition, feedback to centres on 
pre-accrual benchmark cases and prospective/retrospective 
case reviews has been implemented to ensure trial protocol 
adherence.  
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Purpose/Objective: Precise target definition is of paramount 
importance in particle therapy. Inflammatory and post 
surgical alterations may interfere with target contouring. 
Early response evaluation would be clinically useful but is 
still problematic. 18F-FDG may not be the optimal radiodrug 
due to its high uptake in the brain, hindering precise 
evaluation of skull base invasion, and in inflammatory (post-
RT or post surgical) lesions.11C-methionine (MET) PET-CT has 
been reported as an effective alternative in previous studies 
thanks to its low uptake in normal brain and its high uptake 
in salivary gland tumors; however its high uptake in normal 
salivary gland and in oral mucosa may be a limit. 
Materials and Methods: From April 2013 to October 2014, 68 
patients affected by head and neck tumors and treated at 
CNAO with carbon ion radiotherapy have been investigated 
with MET PET–CT. Histology was: adenoid cystic carcinoma 
(60 patients), sarcoma (6 patients) mucoepidermoid 
carcinoma and melanoma (one patient each). Pretreatment 
MET PET-CT, registered and fused with simulation CT, was 
employed as a visual aid in target contouring. MR images (T2 
weighted, T1 weighted and post contrast T1 weighted) were 
also used with the same aim. Volumes with methionine 
uptake comparable with that of parotid glands were included 
in the high dose CTV; asymmetric findings with uptake 
intermediate between parotid and brain were included in the 
low dose CTV. Pre treatment MET failed to show abnormal 
uptake in 17 patients. In patients with elevated initial uptake 
a post treatment MET was performed one month after 
completion of radiotherapy. Pre and post treatment PET is 
available in 24 patients. The ratio between MET uptake in the 
treated volume and uptake in the brain (T/B ratio) was 
calculated pre and post radiotherapy. Dimensional response 
as detectable at MR has been investigated every 3 months 
since the end of radiotherapy.  
Results: Seventeen patients have shown a decrease of more 
than 10% in MET uptake after treatment.The tumor to brain 
ratio has shown a mean reduction of 27%.  
Post radiotherapy changes had a minimal impact on MET 
uptake at one month. The mean follow-up was 8 months and 
the mean volumetric change at the last follow-up was 49%. 
Conclusions: MET PET-CT is a useful tool in contouring and 
early response assessment of head and neck tumors treated 
with carbon ion radiotherapy. Post RT changes do not mask 
tumor response. MET uptake decreases significantly even 
after one month. Longer follow up is needed to correlate 
early MET PET-CT response with long-term outcome.  
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Purpose/Objective: Treatment for resectable locally 
advanced head and neck cancers (LAHNC) is generally 
multimodal, involving surgery followed by radiotherapy (RT) 
± chemotherapy (CT) depending on high-risk features such as 
extracapsular extension (ECE) and R1 resection. The optimal 
duration of overall treatment time (OTT) has been the 
subject of much discussion. Accepted wisdom is that the OTT 
should not exceed 100 days measured from the day of surgery 
to the end of adjuvant therapy. We questioned whether this 
was still true in an era of intensified treatment or whether 
further survival or locoregional control benefits could be 
obtained by using a shorter OTT. 
Materials and Methods: This analysis includes 272 pts. (med. 
F/U 23.9 mo.) with LAHNC (106 oropharynx, 43 
larynx/hypopharynx, 75 oral cavity, 18 nasal/paranasal sinus, 
30 unknown primary/other) treated adjuvantly with RT +/- 
platinum based CT depending on pathological risk factors 
(Gregoire et al 2010). CT was given at a dose of 100mg/ m² 
q21 days or 30 mg/m² weekly. All pts. had IMRT, 2 Gy/ 
fraction to a total dose of 60-66 Gy. Of the 272 pts. 64 (24%) 
had ECE and 201 (74%) were R0 status. 
Pts. were followed at regular intervals with a clinical 
examination, flexible endoscopy and imaging. Toxicity was 
scored according to the RTOG acute radiation morbidity 
criteria and the RTOG/EORTC late radiation morbidity 
criteria.. 
The clinical impact of OTT was assessed using the Kaplan-
Meier and Multivariate Cox regression analysis (MVA). 
Recursive partitioning analysis (RPA) was performed to 
predict an optimal OTT with regard to clinical outcome. 
Results: 223 (82%) pts. had their treatment delivered in <100 
days; 49 (18%) had a duration of ≥ 100 days. Baseline 
characteristics were similar for both groups. MVA identified 
R1 status (HR 2.2) vs R0 status (p=0.36) but not OTT ≥100 
days as an adverse risk factor (ARF) for disease-fre survival 
(DFS). OTT ≥100 days (HR 4.1 vs 100 days; p=0.00007), R1 
status (HR 2.1 vs R0; p=0.04), and ECE (HR 2.3 vs no ECE; 
p=0.0342) were identified as ARFs for overall survival (OS). 
The RPA tree identified OTT <87 days as a high-performance 
group and OTT ≥87 days as the low-performance group for 
DFS. 95 pts. completed their treatment within 87 days and 
110 in ≥87 days. There was no difference in the baseline 
characterstics. 
MVA identified OTT of ≥87 days from surgery to end of RT (HR 
2.2 vs <87 days) and R1 status (HR 2.3 vs R0) as ARFs for DFS. 
